We conducted a small pilot observational study of the effects of bilateral thoracic paravertebral block (BTPB) as an adjunct to perioperative analgesia in coronary artery bypass surgery patients. The initial ropivacaine dose prior to induction of general anaesthesia was 3 mg/kg, which was followed at the end of the surgery by infusion of ropivacaine 0.25% 0.1 ml/kg/hour on each side (e.g. total 35 mg/hour for a 70 kg person). The BTPB did not eliminate the need for supplemental opioids after CABG in the eight patients studied. Moreover, in spite of boluses that were within the manufacturer's recommendation for epidural and major nerve blocks, and an infusion rate that was only slightly higher than what appeared to be safe for epidural infusion, potentially toxic total plasma ropivacaine concentrations were common. We also could not exclude the possibility that the high ropivacaine concentrations were contributing to postoperative mental state changes in the postoperative period. Also, one patient developed local anaesthetic toxicity after the bilateral paravertebral dose. As a result, the study was terminated early after four days. The question of whether paravertebral block confers benefits in cardiac surgery remains unanswered. However, we believe that the bolus dosage and the injection rate we used for BTPB were both too high, and caution other clinicians against the use of these doses. Future studies on the use of BTPB in cardiac surgery patients should include reduced ropivacaine doses injected over longer periods.
Introduction
Thoracic epidural anaesthesia (TEA) may improve analgesia and cardiorespiratory function, and reduce the stress response in patients undergoing coronary artery bypass grafting (CABG) 1 , but the risk of spinal haematoma due to anticoagulation remains a concern 2 . Bilateral thoracic paravertebral blockade (BTPB) potentially confers similar advantages to TEA during CABG, but with reduced risk of a spinal haematoma. As there have been several case reports and series of the use of BTPB for analgesia after CABG, we wished to explore the feasibility, effectiveness, and safety of providing BTPB in CABG patients at our institution. However, we were forced to terminate the study after recruiting only nine patients due to safety concerns related to ropivacaine toxicity. We report our experience as a caution to other clinicians who may be considering BTPB as an alternative to TEA after CABG surgery.
Materials and Methods
With approval from the Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee for a pilot observational study to explore the use of BTPB in CABG (Approval Ref # FM/C/13-CRE9199) and informed written consent of all participants, we recruited consecutive eligible patients undergoing non-emergency CABG surgery at the Prince of Wales Hospital, Hong Kong. The potential benefits of improved cardiac protection and supply-demand balance from sympathetic block, and the risks of regional anaesthesia, including local anaesthetic toxicity, were part of the ethics submission and information provided to patients. Exclusion criteria were: previous thoracic spinal surgery, significant concomitant valvular disease, left ventricular ejection fraction <40%, unstable angina, history of substance abuse, intolerance to ropivacaine and previous cardiac surgery.
Preoperative sedation was with oral midazolam 0.07-0.1 mg/kg. Before general anaesthesia, bilateral thoracic paravertebral catheterisations were performed by one of the authors (AH or MK) at the T3-4 level in an anaesthetic procedure room with standard monitoring. Under aseptic conditions with the patient in the sitting position, an 18G Tuohy needle was inserted 2.5 cm lateral to the thoracic spinous process, and loss of resistance to air with a 5 ml glass syringe was used to identify the paravertebral space 6 as the needle passed through the costotransverse ligament. After negative aspiration, an epidural catheter was then inserted through the Tuohy needle and 3-4 cm of the catheter was left in the paravertebral space. The procedure was then repeated on the opposite side.
With the patient supine and without volume loading, plain ropivacaine 3 mg/kg, diluted with normal saline to a total of 30 ml, was injected through the in situ catheters, half into each paravertebral space simultaneously over 2-3 minutes with intermittent aspiration. This dose was chosen based on the manufacturer's recommendation of up to 3 mg/kg for lumbar epidural, or 4.3 mg/kg for major nerve block 7 . This speed of injection had been used by our group in hundreds of unilateral paravertebral blocks in mastectomy patients with no adverse outcomes 8 . Arterial samples were obtained for plasma ropivacaine concentration measurements; haemodynamic data were recorded immediately prior to the injections, and at 5, 10, 15, 20, and 30 minutes after the injections were completed.
As soon as the injections via the paravertebral catheters were completed and the blocks were assessed using loss of sensation to cold and pinprick, the patients were taken into theatre where monitors were placed followed immediately by the induction of general anaesthesia.
Anaesthesia was induced with intravenous (IV) midazolam 0.025-0.05 mg/kg and fentanyl 2-5 µg/kg, and muscle relaxation was achieved with pancuronium or rocuronium. Maintenance was with midazolam 0.03 mg/kg/hour and fentanyl 5 µg/kg/hour until transfer to the intensive care unit (ICU). Correction of abnormal blood pressure was managed as required with additional fentanyl, isoflurane, nitroglycerine, fluids, or vasopressors.
Patients were anticoagulated with unfractionated bovine heparin 300 IU/kg initially, pre-cardiopulmonary bypass (CPB), plus intermittent boluses to maintain the activated clotting time (ACT) >480 seconds. CPB pump flow rate was maintained between 2.25 and 3.0 l/minute/m 2 and mean arterial pressure between 50-80 mmHg. Antegrade cold blood cardioplegia with or without topical cooling was used. All CPB was near-normothermic. After CPB, once protamine had been given, bilateral paravertebral infusions of ropivacaine 0.25% were commenced at 0.1 ml/kg/hour each side (e.g. total 35 mg/hour for a 70 kg person) and continued for 48 hours. For off-pump cases, heparin 150 IU/kg was used to achieve an ACT of >300 seconds.
In the ICU, patients were given morphine boluses if necessary, 1 mg IV every 5 minutes until adequate pain control was achieved (maximum dose 20 mg over 4 hours).
Each patient's trachea was extubated as soon as appropriate extubation criteria had been met.
As part of monitoring for local anaesthetic toxicity, 1.5 ml blood samples were drawn for plasma total ropivacaine measurement from the indwelling arterial cannula immediately before, and at 5, 10, 20, 30, 45, 60, and 90 minutes after the initial bolus; just prior to CPB; 20-30 minutes into CPB; and at 6, 12, 18, 24, 36 and 48 hours after the initial boluses ( Figure 1 ). The samples were collected into lithium heparin tubes and mixed gently before being placed into ice. In the sampling procedure, a volume of blood exceeding the dead space of the system was first aspirated and discarded. The samples were centrifuged at 3,000 rpm for 10 minutes at room temperature; the plasma was separated and transferred into clean 1.5 ml Eppendorf tubes before being stored at -70°C until assay at a later date when all samples from the patients had been collected. Highperformance liquid chromatography methodology was used to assay the ropivacaine concentration. The limit of detection for ropivacaine was 10 ng/ml. The within-day (intra-assay) coefficient of variation of the assay varied from 5.3% at 100 ng/ml, 1.4% at 500 ng/ml, and 3.9% at 2,000 ng/ml, and the between-day (inter-assay) coefficient of variation was 5.7% at 100 ng/ml, 4.4% at 500 ng/ml, and 8.1% at 2,000 ng/ml. The mean relative extraction efficiency ranged from 82.8% to 96% between 50 and 3,000 ng/ml.
Results
Nine patients were recruited during the first four days of the study. One patient was withdrawn because of ongoing angina before the BTPB commenced. The eight remaining patients had a mean age of 63 years (range 55-72 years), American Society of Anesthesiologists physical status 3-4, and ejection fractions >44%. None had liver disease and all had normal creatinine clearance. One patient had off-pump surgery.
One patient suffered uncontrolled involuntary screaming and uncontrolled tonic-clonic muscular contractions of all four limbs within a minute of completion of the preoperative bilateral ropivacaine boluses. Intermittent aspirations in this patient were negative for blood. The convulsion was terminated immediately with propofol 1 mg/kg IV. No positive pressure bag-mask ventilation or intubation was required. When tested 20 minutes after BTPB injections, he had decreased sensation to cold bilaterally between T2 and T6, although his sensation to pinprick was equivocal. He underwent surgery as planned, but further ropivacaine administration was withheld, and he did not complete the study. His immediate post-injection plasma ropivacaine level was high (Figure 1 ). All other patients completed the pilot study and had successful placement of the blocks as supported by bilateral decreased sensation to cold and pinprick of between 4 and 10 dermatomes between T1 and T12 after the bolus ropivacaine injections, prior to induction of general anaesthesia. All surgical procedures were successfully completed, and separations from CPB were uneventful.
Most of the plasma ropivacaine concentrations peaked above 2.2 µg/ml, the level below which toxic effects are unlikely 10 . This was typically between 5-15 minutes after the initial bilateral bolus injections.
There was no noticeable change (>10%) in blood pressure after BTPB using ropivacaine 3 mg/kg in any patient. No vasopressor was required. The blood pressure also remained stable after general anaesthesia induction in all (eight) patients who received the initial bilateral paravertebral injections.
The time taken to perform the BTPB was 20-30 minutes. None of the patients reported angina during the procedure. On formal questioning at follow-up after discharge to the surgical ward, the patients either did not recall the procedure or reported feeling only slight discomfort.
All seven patients who received the continuous ropivacaine infusion had postoperative neurologic impairment in the form of confusion and combativeness (one patient) or somnolence (six patients). All were disoriented. The altered mental states were much worse than what we normally expected in post-cardiac surgery patients. The BTPBs did not eliminate the need for opioids postoperatively (Figure 2) .
Given the high incidence of probable local anaesthetic toxicity, we terminated the pilot study after the first four days. The decision to terminate was reaffirmed upon receipt of plasma ropivacaine results which became available after the first week.
Discussion
The putative total plasma concentration threshold for increased probability of toxicity for ropivacaine is 2.2 µg/ml 9 . We found that a bolus of ropivacaine 3 mg/kg injected over 2-3 minutes into the thoracic paravertebral space bilaterally resulted in a peak plasma concentration (Cmax) that breached this threshold within 5-15 minutes of the injections in seven of our eight patients (Figure 1 ). One patient developed tonic-clonic contractions, but due to the equivocal response to pinprick testing, an intravascular injection of part or whole of the bolus dose could not be excluded, despite the negative aspiration tests. The remaining six patients with levels ≥2.2 µg/ml 9 did not report symptoms of toxicity, but these may have been masked or affected by the midazolam premedication received by all patients. Our infusion dose was slightly higher than the reported use of an epidural ropivacaine infusion of 30 mg/hour in hip/ knee surgery patients for 72 hours with no clinical toxicity 9 . Those patients' infusions were immediately preceded by a ropivacaine bolus of 50-75 mg 9 , in contrast to our patients' initial boluses which were typically about three hours earlier. Their mean total plasma ropivacaine concentrations were <2.2 µg/ml, the putative total plasma concentration threshold for increased probability of toxicity 10 , at 48 hours 9 .
Ganapathy et al 3 used continuous paravertebral blockade in a case of CABG without cardiopulmonary bypass (CPB) or heparinisation. Dhole et al 4 found that left thoracic continuous paravertebral block was as effective as TEA for analgesia after minimally invasive direct CABG. Cantó et al 5 performed BTPB in a series of 111 elective cardiac surgical patients and found the technique satisfactory except for unwanted sedation.
Our group had prior experience of injecting ropivacaine 2 mg/kg over 2-3 minutes in unilateral thoracic paravertebral blockade in many hundreds of mastectomy patients with no apparent untoward clinical side-effects 8 . In a study of mastectomy patients, Cmax developed within minutes of unilateral thoracic paravertebral injection of 2 mg/kg over 2-3 minutes 8 . In a study of thoracotomy patients, a 20 ml unilateral paravertebral bolus of bupivacaine 0.5% produced a mean Cmax of 1.45 (standard error of mean 0.32) µg/ml at 10-60 minutes 11 . Griffiths et al in 2013 reported that a bolus of ropivacaine 2.5 mg/kg in 40 ml injected as bilateral transverse abdominis plane blocks in healthy women undergoing caesarean section resulted in total plasma concentrations that were >2.2 µg/ml in 18 of 30 participants 10 ; three of the 18 had perioral and tongue paraesthesia, a metallic taste and slurred speech 9 . Unfortunately, this report was published after we had already terminated our pilot study. Based on our experience and these previous reports, as well as the fact that the paravertebral space is highly vascular with rapid systemic absorption, we believe that the bolus dose we used was too high and the rate of injection too rapid.
An infusion of ropivacaine 0.25% at 0.1 ml/kg/hour bilaterally, started after protamine, was associated with deep sedation or combative behavior by postoperative day two. At this time most patients had high plasma ropivacaine concentrations (Figure 1 ). The accumulation of plasma ropivacaine might have been influenced by a transiently lower cardiac output state, resulting in reduced liver blood flow and hepatic clearance of local anaesthetic. A transient lower cardiac output has been reported in some patients after CABG 12 , but we did not specifically measure cardiac output over this period. Moreover, cardiac output may also transiently increase following CABG. A low albumin might also predispose to higher levels 13 . On the other hand, the acute phase α 1 -acid glycoprotein, which binds local anaesthetics, is typically increased, which would reduce the fraction of free ropivacaine 14 . These variables, the free plasma ropivacaine, albumin, liver function, α 1 -acid glycoprotein concentrations and cardiac output were not measured in our study.
There are many causes of altered mental status after surgery, and after CPB in particular. However, from our experience, the mental status of all eight patients was highly unusual and we felt that a likely cause was the high levels of ropivacaine.
After cardiac surgery, an important source of pain is from the sternotomy wound 15 . While the aim of BTPB is to provide analgesia, in our cohort the analgesia was incomplete ( Figure  2) . Part of the reason for the incomplete analgesia from BTPB could be explained by the failure of the block to anaesthesise the low cervical dermatomes which innervate the upper part of the sternum. In comparison, Cantó et al, using BTPB infusion of ropivacaine 0.075% with fentanyl at 0.15 ml/kg/hour each side, was able to achieve good postoperative analgesia with only five out of 109 patients requiring rescue parenteral opioids. The better analgesia achieved in their patients despite using a lower ropivacaine concentration (but at 50% higher infusion rate) might have been because of the inclusion of fentanyl (although the amount of fentanyl added was not clear) and their use of ketorolac 30 mg IV and paracetamol 2 g IV at the end of the surgery 5 .
Summary
In this small pilot observational study, BTPB did not eliminate the need for supplemental opioids after CABG. Moreover, in spite of boluses that were within the manufacturer's recommendation for epidural and major nerve blocks, and an infusion rate that was only slightly higher than what appeared to be safe for epidural infusion, potentially toxic total plasma ropivacaine concentrations were common. We could not exclude the possibility that the high ropivacaine concentrations were contributing to mental state changes in the postoperative period. The question of whether paravertebral block confers benefits in cardiac surgery remains unanswered. However, we believe that the bolus dose and the injection rate we used for BTPB were both too high, and caution other clinicians against the use of these doses. Future studies, if planned, on the use of BTPB in cardiac surgery patients should include reduced ropivacaine bolus doses injected over longer periods.
